Table 3.
Age group (years) | Pre-vaccination IPD incidence (/100,000/year) |
10 years post-vaccination IPD incidence (/100,000/year) |
|||||
---|---|---|---|---|---|---|---|
VT | Strong NVT | Weak NVT | VT | Strong NVT | Weak NVT | IRRa | |
<1 | 67.0 | 21.0 | 7.1 | 6.7 (1.1, 15.1) | 37.0 (29.5, 50.4) | 11.6 (9.4, 15.6) | 0.59 (0.51, 0.72) |
1–5 | 39.3 | 5.1 | 0.7 | 6.4 (1.2, 14.7) | 7.8 (6.5, 10.0) | 1.1 (0.9, 1.4) | 0.34 (0.24, 0.50) |
6–14 | 7.3 | 1.0 | 0.0 | 1.4 (0.3, 3.3) | 1.2 (1.1, 1.5) | 0.0 (0.0, 0.0) | 0.33 (0.20, 0.54) |
15–20 | 1.0 | 0.0 | 0.0 | 0.3 (0.1, 0.5) | 0.0 (0.0, 0.0) | 0.0 (0.0, 0.0) | 0.26 (0.05, 0.54) |
21–49 | 4.2 | 0.9 | 0.0 | 1.2 (0.2, 2.3) | 1.1 (1.0, 1.3) | 0.0 (0.0, 0.0) | 0.45 (0.28, 0.66) |
≥50 | 9.2 | 2.8 | 4.1 | 2.5 (0.5, 5.1) | 3.4 (3.1, 3.9) | 5.3 (4.7, 6.3) | 0.71 (0.60, 0.82) |
All ages | 14.8 | 2.7 | 0.9 | 2.5 (0.5, 5.6) | 4.2 (3.5, 5.3) | 1.3 (1.1, 1.6) | 0.44 (0.34, 0.56) |
The incidence rate ratio (IRR) is between the overall IPD incidence before vaccination and the IPD incidence 10 years post vaccination.